Liver Diseases
As a heterogeneous organ with many vital functions, liver plays a central role in transforming and clearing chemicals thus is susceptible to the toxicity from these agents. Liver suffers the most from drug toxicity, making Drug-Induced Liver Injury (DILI) the leading cause of drug failures. Hepatotoxicity implies chemical-driven liver damage. It can be induced by a drug itself or indirectly by the generation of reactive metabolites. In vitro cell-based toxicity assays could mimic in vivo tissue studies and in turn provide a reliable tool for safety evaluation in early stages of drug discovery. Stellixir, provides a series of in vitro models and assays to help researchers assess drug hepatotoxicity potential in the preclinical stage.
We Offer-
- Innovative efficacy assays on Hepatology
- Test the safety of your drugs or active molecule products in preclinical researches
- Customized services for special requirements on efficacy or safety tests
We have developed a multiplexed hepatotoxicity assays using various in vitro hepatology models, such as primary hepatocytes, HepG2 cell lines and 3D hepatic models to predict DILI. Our experienced scientists will assist you with meeting your objectives and support your projects.
In Vitro Hepatotoxicity Testing Models
- 2D Cell Based Models: Various 2D culture models including HepG2 cell line, human primary hepatocytes and iPSC-derived hepatocytes for investigation of potential adverse hepatotoxicity.
- 3D Hepatotoxicity Screening Models: 3D cell culture models derived from hepatocytes of several different species.
Stellixir is able to provide you with highly reliable data on drug hepatotoxicity. We have the infrastructure and team to test the drug’s safety or even the active molecule products using preclinical research. The customized services are the latest, with an experienced team backing that meets your needs, promising better efficacy and safety measures.
Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
Discovery Services:
- Establishing NASH conditions by elevated glucose and fructose levels, free fatty acids and lipopolysaccharide, and LPS treatment.
- Cytotoxicity assays
- Cytokines analysis: IL-6, TNF-α, MIP-1α (CCL3), MCP-1, IP-10 (CXCL10), IL-8 (CXCL8)
- Expression of profibrotic markers
- Apoptosis marker studies
- Oxidative stress marker studies
- Mitochondrial dysfunction studies
- Cellular lipids and phospholipids estimation by LipidTox staining
Available Models:
- Human liver microtissues contain primary human hepatocytes (PHHs), liver endothelial cells (LECs), Kupffer cells (KCs) and hepatic stellate cells (HSCs) at a physiologically relevant ratios
- 2D and 3D cultures of HepG2, HuH 7, and HepaRG cells
- 3D Hepatospheres of human iPSCs
Techniques Used: Flow Cytometry, Confocal/Fluorescence Microscopy (Multi-colour Immunofluorescence), ELISA (Fluorimetry/Colorimetry), RTqPCR, WB.